摘要目的 探讨125I粒子前列腺植入近距离放射治疗去势抵抗性前列腺癌(CRPC)的临床疗效.方法 回顾性分析2010年2月至2015年12月间本院收治的28例CRPC患者的临床资料,根据治疗方案不同分为对照组(13例)和观察组(15例),分别行单纯内分泌治疗和超声引导下经会阴穿刺125I粒子植入联合内分泌治疗,比较2组患者术后前列腺特异性抗原(PSA)-无进展生存期(P FS)、总生存期(OS)和生活质量(生理功能、社会功能、总健康水平、一般躯体不适、尿路症状和治疗相关症状).采用Kaplan-Meier分析和log-rank检验分析数据.结果 观察组患者中位PSA-PFS、OS分别为29(24,37)个月和37(32,50)个月,高于对照组的13(7,21)、19(14,23)个月(x2=13.300和19.362,均P＜0.01).观察组患者生理功能、社会功能、总健康水平和一般躯体不适对应评分较对照组均有提高.结论 近距离放射治疗CRPC能有效延长患者生存期,且在一定程度上提高患者生活质量.

abstractsObjective To evaluate the clinical efficacy of brachytherapy with 125I seeds implantation in patients with castration resistant prostate cancer (CRPC).Methods Twenty-eight patients with CRPC from February 2010 to December 2015 in Northern Jiangsu People's Hospital were analyzed retrospectively.Patients were divided into 2 groups according to different treatment methods.Control group (n =13) received endocrine therapy,and study group (n =15) underwent brachytherapy combined with endocrine therapy.The progression was defined as posttreatment prostate specific antigen (PSA) ≥ 125％ PSA of baseline level.PSA-progression-free survival (PFS),overall survival (OS) and quality of life (physical functioning,social functioning,general health,general physical discomfort,urinary symptoms and treatment-related symptoms) of 2 groups were compared using Kaplan-Meier analysis and log-rank test.Results The median PSA-PFS and OS of study group were 29(24,37) months and 37(32,50) months respectively,both of them were longer than those of control group (13(7,21) months,19(14,23) months;x2 =13.300,19.362,both P＜0.01).Comparing with control group,the physical functioning,social functioning,general health and general physical discomfort of study group were improved.Conclusion Brachytherapy can effectively prolong the survival of CRPC patients and improve the patients' life quality.